StageSeries E | Alive
Last Raised$100M | 2 yrs ago
Mosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
+20 points in the past 30 days
Color operates as healthcare technology company. democratizes access to genetic information. It offers Color Test for patients to detect hereditary cancers such as breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers. It was formerly known as Color Genomics. It was founded in 2013 and is based in Burlingame, California.
ESPs containing Color
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The D2C genetic tests market refers to the direct-to-consumer genetic testing category, where individuals can purchase genetic tests without a healthcare provider's involvement. The market promises to provide personalized insights into an individual's genetic makeup, health risks, ancestry, and inherited traits. However, there are concerns about the accuracy and interpretation of results, as well …
Color named as Leader among 6 other companies, including Helix, Ancestry, and Human Longevity.
Compete with Color?
Ensure that your company and products are accurately represented on our platform.
Color's Products & Differentiators
Color’s behavioral health offering is designed to bring high-quality care to more people, where they are, when they need it. Our platform supports public health departments and school districts to reach, screen, and connect more people to care, faster. Including billing management, Medicaid enrollment, and other billing support. We embed in communities we serve, supporting canvassing and awareness-building through schools, libraries and more. We provide frontline staff training and support, including support hotlines. We can help onboard counselors and clinicians in your community or system, improving efficiency from existing teams and access. Real-time reporting on utilization, outcomes, and risks to ensure the right kind of care is reaching your community. HIPAA-compliant platform Color takes security and privacy seriously.
Research containing Color
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Color in 7 CB Insights research briefs, most recently on Dec 19, 2022.
Nov 11, 2020Genomics Business Model Spotlight: Helix
Expert Collections containing Color
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Color is included in 10 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare
Digital Health 150
2019's cohort of the most promising digital health startups transforming the healthcare industry
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Health Monitoring & Diagnostics
Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance
Color has filed 29 patents.
The 3 most popular patent topics include:
- Diseases of the eye and adnexa
- Monoclonal antibodies
Machine learning, Artificial intelligence, Data mining, Software testing, Bioinformatics
Machine learning, Artificial intelligence, Data mining, Software testing, Bioinformatics
Latest Color News
Apr 24, 2023
" - https://www.reportlinker.com/p06451113/?utm_source=GNW , Color Health, CooperSurgica Inc., OPKO Health Inc., Illumina Inc., Laboratory Corporation of America Holdings, Pathway Genomics Corporation, Strand Life Sciences Private Limited, Progenity Inc., Myogenes, Counsyl, and ARUP Laboratories. The global hereditary cancer testing market is expected to grow from $3.55 billion in 2022 to $3.95 billion in 2023 at a compound annual growth rate (CAGR) of 11.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The hereditary cancer testing market is expected to grow to $5.82 billion in 2027 at a CAGR of 10.2%. The hereditary cancer testing market includes revenues earned by entities by providing hereditary cancer testing for lung cancer, cervical cancer, prostate cancer, stomach/gastric cancer, melanoma, sarcoma, and uterine cancer.The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The hereditary cancer testing refer to testing methods for hereditary cancers which can identify specific hereditary cancer diseases and disease-related gene mutations.This testing may decrease the risk of developing particular cancer mutants allowing for comprehensive cancer risk for patients. The primary purpose of this cancer testing is to detect hereditary cancer early and maximize patient health outcomes. This testing procedure assists in identifying cancers that one has a genetic risk and allows them to receive preventive treatment. North America was the largest region in the hereditary cancer testing market in 2022. The regions covered in the hereditary cancer testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The main types of tests of hereditary cancer testing are multi panel test and single-site genetic test.The multi panel test refers to hereditary cancer test that is used to detect many chemicals simultaneously. Panels come in a variety of types, from three-panel tests that look for three substances to five, seven, to 12-panel tests.The choice of conducting required number of tests is up to a tester’s discretion. The hereditary cancer testing is conducted for detecting breast cancer, ovarian cancer, colorectal cancer, and other indications that are used in hospitals, clinics, and diagnostic centers. The increasing prevalence of hereditary cancer is expected to drive the hereditary cancer testing market.Mutations in specific genes passed down from parents to children cause hereditary cancer syndromes. Hereditary cancer testing can detect specific, heritable, disease-related gene mutations, allowing for a comprehensive cancer risk assessment for patients.For instance, in June 2022, according to an article published on BioMed Central about hereditary cancer in clinical practice states that about 10% of pancreatic cancer cases have a genetic background. Furthermore, in May 2021, a Europe-based SOPHiA genetics, a data-driven medicine software company, stated in an article that hereditary accounts for approximately 10% of cancer cases, with an estimated 20% of cancer patients having cancer family history. Therefore, the increasing prevalence of hereditary cancer drives the growth of the hereditary cancer testing market. Technological innovation is a key trend gaining popularity in the hereditary cancer testing market.Key players in the market are focusing on technological innovations to sustain their market position. For instance, in March 2022, Myriad Genetics, US-based genetic testing and precision medicine company, launched genetic testing with Polygenic Breast Cancer Risk Assessment Score for all ancestries. This MyRisk Hereditary Cancer test with RiskScore offers a personalized breast cancer risk assessment to all women who have never been diagnosed with breast cancer, regardless of ancestry. In January 2020, Quest Diagnostics, a US-based clinical laboratory company, acquired Blueprint Genetics for an undisclosed amount.With this acquisition Quest and Blueprint Genetics will improve patient care and pharmaceutical medication research and development by increasing access to practical insights into genetic and rare diseases. Blueprint Genetics is a US-based company offering complete genetic testing and genetic diagnostics to medical professionals. The countries covered in the hereditary cancer testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The hereditary cancer testing market research report is one of a series of new reports that provides hereditary cancer testing market statistics, including hereditary cancer testing industry global market size, regional shares, competitors with a hereditary cancer testing market share, detailed hereditary cancer testing market segments, market trends and opportunities, and any further data you may need to thrive in the hereditary cancer testing industry. This hereditary cancer testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Color Frequently Asked Questions (FAQ)
When was Color founded?
Color was founded in 2013.
Where is Color's headquarters?
Color's headquarters is located at 839 Mitten Road, Burlingame.
What is Color's latest funding round?
Color's latest funding round is Series E.
How much did Color raise?
Color raised a total of $496.04M.
Who are the investors of Color?
Investors of Color include General Catalyst, Viking Global Investors, Emerson Collective, T. Rowe Price, Kindred Ventures and 22 more.
Who are Color's competitors?
Competitors of Color include LetsGetChecked, Human Longevity, Cerner, Nalagenetics, Transcarent and 13 more.
What products does Color offer?
Color's products include Behavioral Health and 4 more.
Who are Color's customers?
Customers of Color include CDPH, MADPH, CDC and NIH.
Compare Color to Competitors
OmeCare provides physicians and their patients with genetic information to improve or maintain health and wellness. The company's mobile health applications merge artificial intelligence and deep learning with personal genetic information that provides personalized health and wellness guidance.
Everly Health provides an e-commerce platform. It enables customers to buy a variety of test kits online, collect their samples at home, and get results without visiting a lab or doctor's office. It offers various at-home lab tests such as sexual health, thyroid, metabolism, men's health, and more. The company was formerly known as Everly Well. It was founded in 2015 and is based in Austin, Texas.
Genomelink develops a personal discovery platform where people store deoxyribonucleic acid (DNA) data to access more insights, products, and medical research. The company platform allows the member to upload their DNA data file and discover their identities and traits. It was founded in 2017 and is based in Berkeley, California.
Ancestry offers a website offering family history information, historical records and other genealogical information. Ancestry.com offers several localized Web sites designed to empower people to discover, preserve and share family history. Ancestry has more than 2.2 million paying subscribers across its core Ancestry websites and approximately 1.5 million DNA samples in the AncestryDNA database.
LeanTaaS provides software solutions that combine lean principles, predictive analytics, and machine learning for core operational processes in hospital and infusion center operations. LeanTaaS increases patient access, decreases wait times, improves staff satisfaction, reduces healthcare delivery costs, and improves operational performance. The company was founded in 2010 and is based in Santa Clara, California.
Careful Online provides a healthcare patient tracking app. The company provides a patient tracking system that allows healthcare workers to share and log patients' clinical information using cloud-based software. It targets both public and private healthcare providers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.